To the central content area :::


Listed Companies

:::Listed Companies > Listed Companies Info. > Emerging Stock Board Companies > Listed Company Profile

ESM Companies

For foreign Emerging Stock Board enterprises, ”*- country of incorporation” indicates stocks without par value or with par value other than NT$10, and ”- country of incorporation” indicates stocks with par value of NT$10 per share.
6696 LBS
Basic information
Chairman President Spokesperson Telephone Address ESM Registration Date
Tom Lin Irene Wang Irene Wang 02-87805008 36F, No.68, Sec.5, Zhongxiao E. Rd., Xinyi Dist.Taipei City 11065, Taiwan 2018/10/08
Key businesses
Biotechnology and Medical Care Lin BioScience is a new drug development company specializing in innovative therapies for unmet medical need. Its pipeline consists of 4 first-in-class drugs (008, 009, 007 and 002) and 2 technology platform (RBP4 and CDC7 platform) aimed at treating diseases in metabolic, ophthalmology, and oncology. LBS adopts a fast track development strategy as each drug targets both a blockbuster indication and an orphan disease indication. This allows the drug to be approved in a much faster speed while maintaining the great financial upside. Both 008, an oral therapy for Dry AMD, and 009, an oral therapy for Fatty Liver Disease, are developed from our RBP4 platform. 008 is the most advanced candidate from the US NIH's highly selective Blueprint Program and has obtained Rare Pediatric Disease and Orphan Drug designation from FDA. 007, developed from our CDC7 platform, is a natural cell cycle CDC7 inhibitor targeting a variety of hard to treat cancers such as leukemia and solid tumors.
Market info
Latest trading info Historic trading info
Financial data
Cash flows statement Item
Amount(NTD, in thousands)
Cash flows from operating activities
Cash flows from investing activities
Cash flows from financing activities
balance sheet
Current assets
Non-current assets
Total assets
Current liabilities
Non-current liabilities
Total liabilities
Share capital
Capital surplus
Retained earnings
Other equity interest
Treasury shares
Total equity attributable to owners of parent
Non-controlling interests
Total equity
Book Value per share(NT$)
profit and loss
Operating revenue
Operating costs
Gross profit from operations
Operating expenses
Net other income (expenses)
Net operating income
Non-operating income and expenses
Profit before tax
Tax expense
Profit from continuing operations
Profit from discontinued operations
Other comprehensive income
Comprehensive income
Basic earnings per share
 Auditor's report on latest financial statements: auditor's report:
 Investors may find more detailed information on the company by visiting the Market Observation Post System.。
 The information disclosed here concerning foreign enterprises consists of amounts provided in consolidated financial statements.